drugset
drugset / Trial / NCT05875428

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05875428 ↗

Phase 2 Unknown 104 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A multicenter, single-arm, phase 2 study of mitoxantrone hydrochloride liposome injection in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Timeline

Start
2023-07-10
Primary completion
2024-12-31
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma